PMID- 27814617
OWN - NLM
STAT- MEDLINE
DCOM- 20180105
LR  - 20220223
IS  - 2768-6698 (Electronic)
IS  - 2768-6698 (Linking)
VI  - 22
IP  - 2
DP  - 2017 Jan 1
TI  - Tumor abolition and antitumor immunostimulation by physico-chemical 
      tumor ablation.
PG  - 310-347
AB  - Tumor ablation by thermal, chemical and radiological sources has received 
      substantial attention for the treatment of many localized malignancies. The 
      primary goal of most ablation procedures is to eradicate all viable malignant 
      cells within a designated target volume through the application of energy or 
      chemicals. Methods such as radiotherapy, chemical and biological ablation, 
      photodynamic therapy, cryoablation, high-temperature ablation (radiofrequency, 
      microwave, laser, and ultrasound), and electric-based ablation have been 
      developed for focal malignancies. In recent years a large volume of data emerged 
      on the effect of in situ tumor destruction (ablation) on inflammatory and immune 
      components resulting in systemic anti-tumor reactions. It is evident that in situ 
      tumor ablation can involve tumor antigen release, cross presentation and the 
      release of DAMPS and make the tumor its own cellular vaccine. Tumor tissue 
      destruction by in situ ablation may stimulate antigen-specific cellular immunity 
      engendered by an inflammatory milieu. Dendritic cells (DCs) attracted to this 
      microenvironment, will undergo maturation after internalizing cellular debris 
      containing tumor antigens and will be exposed to damage associated molecular 
      pattern (DAMP). Mature DCs can mediate antigen-specific cellular immunity via 
      presentation of processed antigens to T cells. The immunomodulatory properties, 
      exhibited by in situ ablation could portend a future collaboration with 
      immunotherapeutic measures. In this review are summarized and discuss the 
      preclinical and clinical studies pertinent to the phenomena of stimulation of 
      specific anti-tumor immunity by various ablation modalities and the immunology 
      related measures used to boost this response.
FAU - Keisari, Yona
AU  - Keisari Y
AD  - The Roberts-Guthman Chair of Immunopharmacology, Department of Clinical 
      Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, 
      6997801 Tel Aviv, Israel, ykeisari@post.tau.ac.il.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20170101
PL  - Singapore
TA  - Front Biosci (Landmark Ed)
JT  - Frontiers in bioscience (Landmark edition)
JID - 101612996
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Animals
MH  - Cancer Vaccines/therapeutic use
MH  - Combined Modality Therapy
MH  - Humans
MH  - Hyperthermia, Induced/methods
MH  - Immunization/methods
MH  - Immunotherapy/methods
MH  - Molecular Targeted Therapy/methods
MH  - Neoplasms/*immunology/*therapy
MH  - Photochemotherapy/methods
EDAT- 2016/11/05 06:00
MHDA- 2018/01/06 06:00
CRDT- 2016/11/05 06:00
PHST- 2016/11/05 06:00 [entrez]
PHST- 2016/11/05 06:00 [pubmed]
PHST- 2018/01/06 06:00 [medline]
AID - 4487 [pii]
AID - 10.2741/4487 [doi]
PST - epublish
SO  - Front Biosci (Landmark Ed). 2017 Jan 1;22(2):310-347. doi: 10.2741/4487.